Concord Labs

Concord Biotech is a leading global biotechnology company specializing in the development and manufacture of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. Headquartered in India, the company is a dominant player in the global immunosuppressant market, providing critical components for organ transplant medications such as Tacrolimus, Sirolimus, and Cyclosporine. Concord's vertically integrated business model encompasses R&D, large-scale fermentation, and manufacturing facilities approved by major regulatory bodies including the US FDA and EU GMP. The company serves over 70 countries and has expanded its portfolio into high-growth therapeutic areas such as oncology, anti-fungals, and anti-infectives. Following its successful initial public offering in 2023, Concord Biotech continues to leverage its specialized fermentation platform to provide both proprietary products and contract development and manufacturing (CDMO) services to the global pharmaceutical industry.